Skip to main content
Skip to footer
Medical Professionals
Information for Healthcare Providers
Clinical Studies
Expanded Access
Educational Grants
Request Information
Press Releases
Suppliers
Atara Biotherapeutics
Our Company
About Us
Responsibility
Technology
Technology
Manufacturing
CAR T
Pipeline
Atara Pipeline
Tab-cel
®
ATA3219
ATA3431
Patients & Families
Our Mission
ATA3219 Trial (NHL)
ATA3219 Trial (SLE/LN)
Stories of Strength
About EBV
PTLD
Clinical Studies
Expanded Access
Investors & Media
Investors & Media
News & Events
Financial Results
ATRA Stock
Analyst Coverage
SEC Filings
Governance
Careers
Careers Home
Career Areas
Job Search
Contact
Medical Professionals
Press Releases
Suppliers
LinkedIn
Twitter
News
Careers
Optimization and Characterization of ATA3219: A Novel and Potent Allogeneic CD19-CAR T Therapy Without Gene Editing